文献速递细菌感染、耐药与抗菌药物

金黄色葡萄球菌菌血症的临床亚表型

Clinical Subphenotypes of Staphylococcus aureus Bacteremia.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该研究纳入3个成人单一菌种金黄色葡萄球菌菌血症队列(英国爱丁堡回顾性观察队列458例、英国ARREST试验758例、西班牙SAFO试验214例),用潜在类别分析在不考虑结局的情况下识别出5个可重复的临床亚表型,各亚表型间死亡率和微生物学结局存在差异,ARREST试验二次分析提示辅助利福平在不同亚表型中效应不同。

要点

  • 基于常规临床数据识别出5个可重复的金黄色葡萄球菌菌血症临床亚表型。
  • 亚表型A死亡率最高,亚表型B和E死亡率最低,亚表型C微生物学结局更差。
  • ARREST试验二次分析中,辅助利福平与亚表型B死亡率增加及亚表型C微生物学结局改善相关。

核心结论

  • 在金黄色葡萄球菌菌血症中识别出可重复且临床相关的亚表型,并提供了治疗效应存在差异的原理验证。
  • 通过临床试验富集和患者分层,这些亚表型可能有助于金黄色葡萄球菌菌血症的个体化医疗。

研究设计与样本

  • 研究纳入3个成人单一菌种金黄色葡萄球菌菌血症队列:英国回顾性观察研究(爱丁堡队列,n=458)、英国ARREST试验(n=758)和西班牙SAFO试验(n=214)。
  • 采用潜在类别分析,在不考虑结局的情况下基于常规收集的临床数据识别亚表型,随后比较各亚表型间的死亡率和微生物学结局。

主要发现

  • 纳入患者以甲氧西林敏感金黄色葡萄球菌菌血症为主(1430例中1366例,95.5%)。
  • 识别出5个不同且可重复的临床亚表型:A为与高龄和合并症相关的菌血症,B为无合并症年轻者的院内静脉导管相关菌血症,C为社区获得性转移性菌血症,D为与慢性肾脏病相关的菌血症,E为与注射吸毒相关的菌血症。
  • 各亚表型间生存和微生物学结局存在差异:亚表型A死亡率最高,亚表型B和E死亡率最低,亚表型C微生物学结局更差。
  • 在ARREST试验的二次分析中,辅助利福平与亚表型B死亡率增加相关,并与亚表型C微生物学结局改善相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Staphylococcus aureus bacteremia (SAB) is a clinically heterogeneous disease. The ability to identify subgroups of patients with shared traits (subphenotypes) is an unmet need to allow patient stratification for clinical management and research. We aimed to test the hypothesis that clinically relevant subphenotypes can be reproducibly identified among patients with SAB. METHODS: We studied 3 cohorts of adults with monomicrobial SAB: a UK retrospective observational study (Edinburgh cohort, n = 458), the UK ARREST trial (n = 758), and the Spanish SAFO trial (n = 214). Latent class analysis was used to identify subphenotypes using routinely collected clinical data without considering outcomes. Mortality and microbiologic outcomes were then compared between subphenotypes. RESULTS: Included patients had predominantly methicillin-susceptible SAB (1366 of 1430, 95.5%). We identified 5 distinct, reproducible clinical subphenotypes: (A) SAB associated with older age and comorbidity, (B) nosocomial intravenous catheter-associated SAB in younger people without comorbidity, (C) community-acquired metastatic SAB, (D) SAB associated with chronic kidney disease, and (E) SAB associated with injection drug use. Survival and microbiologic outcomes differed between the subphenotypes. Mortality was highest in subphenotype A and lowest in subphenotypes B and E. Microbiologic outcomes were worse in subphenotype C. In a secondary analysis of the ARREST trial, adjunctive rifampicin was associated with increased mortality in subphenotype B and improved microbiologic outcomes in subphenotype C. CONCLUSIONS: We have identified reproducible and clinically relevant subphenotypes within SAB and provide proof of principle of differential treatment effects. Through clinical trial enrichment and patient stratification, these subphenotypes could contribute to a personalized medicine approach to SAB.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Swets MC, Bakk Z, Westgeest AC, et al. Clinical Subphenotypes of Staphylococcus aureus Bacteremia. Clin Infect Dis. 2024. PMID: 38916975. doi:10.1093/cid/ciae338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。